Intellia Therapeutics Inc (DE:38I)
NASDAQ:38I
38I Stock Chart & Stats
€10.86
-€0.50(-4.02%)
At close: 4:00 PM EST
€10.86
-€0.50(-4.02%)
Day’s Range― - ―
52-Week Range€5.30 - €24.34
Previous CloseN/A
Volume0.00
Average Volume (3M)249.00
Market Cap
€1.36B
Enterprise Value€1.40B
Total Cash (Recent Filing)€449.88M
Total Debt (Recent Filing)€93.33M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Apr 30, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding118,133,545
10 Day Avg. Volume131
30 Day Avg. Volume249
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.86Price Target Upside64.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)-3.12
Revenue Forecast (FY)€50.61M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsClinical data showed stabilization in walking distance and robust suppression of the disease biomarker, indicating potential functional benefit across a range of patients and supporting the therapy's efficacy case.
Physician Demand And Related Program EnrollmentHigh physician interest and stronger-than-expected enrollment in the hereditary angioedema program with lonvo-z, with no severe liver safety signal observed, supports commercial enthusiasm for one‑time gene‑editing approaches.
Regulatory ClearanceU.S. regulator lifted the clinical hold on the pivotal ATTR-CM trial after agreement on enhanced liver monitoring and exclusion criteria, allowing enrollment to resume and removing a major program uncertainty.
Bears Say
Enrollment And Execution ConstraintsStricter exclusion criteria, enhanced liver monitoring, and steroid guidance could reduce the eligible patient pool and increase operational burden, slowing enrollment and weakening the program's commercial and statistical prospects.
Payer Resistance To PricingHigh upfront pricing for a one‑time irreversible therapy faces potential payer pushback, creating a significant commercial barrier to achieving broad access and reimbursement.
Safety-related Adoption RiskA patient who met serious liver injury criteria and subsequently died prompted analyst downgrade and heightened safety concerns, which could materially limit uptake of an irreversible therapy given safer alternatives.
Intellia Therapeutics News
38I FAQ
What was Intellia Therapeutics Inc’s price range in the past 12 months?
Intellia Therapeutics Inc lowest stock price was €5.30 and its highest was €24.34 in the past 12 months.
What is Intellia Therapeutics Inc’s market cap?
Intellia Therapeutics Inc’s market cap is €1.36B.
When is Intellia Therapeutics Inc’s upcoming earnings report date?
Intellia Therapeutics Inc’s upcoming earnings report date is Apr 30, 2026 which is in 33 days.
How were Intellia Therapeutics Inc’s earnings last quarter?
Intellia Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -€0.719 earnings per share for the quarter, beating the consensus estimate of -€0.827 by €0.108.
Is Intellia Therapeutics Inc overvalued?
According to Wall Street analysts Intellia Therapeutics Inc’s price is currently Undervalued.
Does Intellia Therapeutics Inc pay dividends?
Intellia Therapeutics Inc does not currently pay dividends.
What is Intellia Therapeutics Inc’s EPS estimate?
Intellia Therapeutics Inc’s EPS estimate is -0.79.
How many shares outstanding does Intellia Therapeutics Inc have?
Intellia Therapeutics Inc has 118,133,545 shares outstanding.
What happened to Intellia Therapeutics Inc’s price movement after its last earnings report?
Intellia Therapeutics Inc reported an EPS of -€0.719 in its last earnings report, beating expectations of -€0.827. Following the earnings report the stock price went up 4.803%.
Which hedge fund is a major shareholder of Intellia Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:38I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€17.86 (64.47% Upside)
€17.86 (64.47% Upside)
Blogger Sentiment
Bullish
DE:38I Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $897.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.32%
12-Months-Change
Fundamentals
Return on Equity
-56.63%
Trailing 12-Months
Asset Growth
-29.29%
Trailing 12-Months
Company Description
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
38I Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.View all DE:38I earnings summaries38I Revenue Breakdown
100.00% Collaboration revenue
38I Stock 12 Month Forecast
Average Price Target
€17.86
▲(64.47% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Options Prices
Currently, No data available
---